ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1212

Elevated Fecal Secretory Immunoglobulin A, Anti-Cyclic Citrullinated Peptide Antibodies, and Cytokine Levels in Rheumatoid Arthritis Patients

Sam Dalvi1, Jose U. Scher*1, Mukundan Attur2, Jyoti Patel3 and Steven B. Abramson4, 1Rheumatology, NYU Hospital for Joint Diseases, New York, NY, 2Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, 3Rheumatology, NYU Langone Medical Center, New York, NY, 4Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: cytokines, immunoglobulin (IG) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumamtoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is a complex autoimmune disease with genetic and environmental contributions. There has been increasing interest in the microbiome and its potential contribution to the pathogenesis of the inflammatory arthritides. Our recent study suggest that RA patients have altered intestinal microbiota compared to healthy controls. Here we aimed to investigate the local immunologic response in the intestinal tract of RA patients, including humoral signatures and pro-inflammatory cytokine profile. Mucosal response against enteric bacteria may offer insights into the pathogenesis of RA and the potential identification of subsets of patients amenable to therapeutic interventions.

Methods: RA status, clinical activity and sociodemographic factors were determined in patients with New-onset RA (NORA; n=15), Chronic-established RA (CRA; n=14), and matched healthy subjects (n=14). Fecal samples were obtained and total protein was extracted. ELISA assays were performed to determine concentrations of secretory (s) IgA, anti-cyclic citrullinated peptides antibodies (anti-CCP3.1), and various pro-inflammatory cytokines by multiplex assay.

Results: RA patients show aberrant intestinal humoral responses manifested by elevated fecal sIgA levels. Elevated levels of anti-CCP antibodies were found in fecal samples of these patients (mean= 64.9 Units vs 14.7 Units in healthy controls; P=0.03), suggesting that the intestinal tract is a potential site for peptide citrullination. Intriguingly, the gut anti-CCP3.1 levels in CRA patients were higher compared to NORA (p=0.10).  NORA patients have significantly elevated fecal IL-1β compared to controls (mean= 4.2 pg/ml vs 1.67, p=0.02) as well as other pro-inflammatory cytokines including TNFa. These changes are associated with an intestinal microbiota alteration in NORA patients, characterized by a higher prevalence of Prevotella spp.

Conclusion: Our results show evidence of an amplified adaptive immune response and subclinical inflammation within the intestinal tract of patients with RA. To our knowledge, detection of the aforementioned fecal immunoglobulins and cytokines in RA patients has not been previously described. These findings suggest that immunologic defense mechanisms against intestinal bacteria may play a role in the pathogenesis of RA and that the intestinal tract is a potential site of peptide citrullination. Further studies are warranted to validate our findings.


Disclosure:

S. Dalvi,
None;

J. U. Scher*,
None;

M. Attur,
None;

J. Patel,
None;

S. B. Abramson,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elevated-fecal-secretory-immunoglobulin-a-anti-cyclic-citrullinated-peptide-antibodies-and-cytokine-levels-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology